MedTrace Logo

Efficacy of N-Acetyl-Cysteine in Bipolar Disorder and Tobacco Use Disorder

NCT02252341 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2015-04-17

No results posted yet for this study

Summary

Effects of N-Acetyl-Cysteine in patients with bipolar depression (primary outcome is Hamilton Depression Rating Scale) with and without tobacco use disorder and on inflammatory and oxidative stress biomarkers

Conditions

Interventions

DIETARY_SUPPLEMENT

N-Acetyl-Cysteine

drug: N-Acetyl-cysteine N-Acetyl-cysteine 1800 mg a day for 12 weeks versus placebo for 12 weeks

Sponsors & Collaborators

  • Universidade Estadual de Maringá

    lead OTHER

Principal Investigators

  • Sandra Nunes, M.D, Ph.D · Universidade Estadual de Londrina

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2015-09-30
Completion
2015-09-30

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02252341 on ClinicalTrials.gov